Preclinical Testing of FDA-Approved Drugs Repurposed for Potential Novel Tocolytic Use.

被引：0
|
作者：
Siricilla, Shajila [1 ]
Hansen, Christopher J. [2 ]
Staub, Jeremy D. [1 ]
Walker, Jordan [2 ]
Brown, Alexus J. [1 ]
Benjamin, John [1 ]
Herington, Jennifer L. [1 ,2 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[2] Vanderbilt Univ, Nashville, TN USA
来源：
REPRODUCTIVE SCIENCES | 2024年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
T-018
引用
收藏
页码：119A / 120A
页数：2
相关论文
共 50 条
  • [41] Identification of FDA-approved drugs as novel allosteric inhibitors of human executioner caspases
    Deepak, R. N. V. Krishna
    Abdullah, Ahmad
    Talwar, Priti
    Fan, Hao
    Ravanan, Palaniyandi
    PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2018, 86 (11) : 1202 - 1210
  • [42] USE OF FDA-APPROVED DRUGS IN VETERINARY-MEDICINE - PROHIBITIONS, PREROGATIVES, AND RESPONSIBILITIES
    POWERS, TE
    JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 1993, 202 (10) : 1608 - 1608
  • [43] Pharmacogenomic characterization of US FDA-approved cytotoxic drugs
    Peters, Eric J.
    Motsinger-Reif, Alison
    Havener, Tammy M.
    Everitt, Lorraine
    Hardison, Nicholas E.
    Watson, Venita G.
    Wagner, Michael
    Richards, Kristy L.
    Province, Mike A.
    McLeod, Howard L.
    PHARMACOGENOMICS, 2011, 12 (10) : 1407 - 1415
  • [44] RNA as an off-target for FDA-approved drugs
    Fullenkamp, Christopher R.
    Schneekloth, John S.
    NATURE CHEMISTRY, 2023, 15 (10) : 1329 - 1331
  • [45] Pharmacogenetic Labeling of FDA-Approved Drugs A Regulatory Retrospective
    Drozda, Katarzyna
    Pacanowski, Michael A.
    Grimstein, Christian
    Zineh, Issam
    JACC-BASIC TO TRANSLATIONAL SCIENCE, 2018, 3 (04): : 545 - 549
  • [46] An analysis of FDA-approved drugs: natural products and their derivatives
    Patridge, Eric
    Gareiss, Peter
    Kinch, Michael S.
    Hoyer, Denton
    DRUG DISCOVERY TODAY, 2016, 21 (02) : 204 - 207
  • [47] Preapproval Promises to Voluntarily Withdraw FDA-Approved Drugs
    Lynch, Holly Fernandez
    Sachs, Rachel E.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (24): : 2392 - 2393
  • [48] Screening of FDA-Approved Drugs for Treatment of Emerging Pathogens
    Sisk, Jeanne M.
    Frieman, Matthew B.
    ACS INFECTIOUS DISEASES, 2015, 1 (09): : 401 - 402
  • [49] An analysis of FDA-approved drugs for inflammation and autoimmune diseases
    Kinch, Michael S.
    Merkel, Janie
    DRUG DISCOVERY TODAY, 2015, 20 (08) : 920 - 923
  • [50] RNA as an off-target for FDA-approved drugs
    Christopher R. Fullenkamp
    John S. Schneekloth
    Nature Chemistry, 2023, 15 : 1329 - 1331
12345